leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma says studies validate the use of interferon in treating COVID-19

Recent studies indicated that interferon a2b significantly accelerated clearance of the virus from patient airways and reduced inflammatory proteins thought to cause severe COVID-19 complications

BetterLife Pharma Inc -
One study looked at the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) told shareholders Friday that recent findings support the use of a new proprietary inhalation treatment called interferon alpha-2b (a2b) for coronavirus.

The pharmaceutical development company is exploring the potential of using interferon as a treatment for coronavirus, or COVID-19.

Findings published in the May 15 issue of 'Frontiers of Immunology' indicated that interferon a2b significantly accelerated clearance of the virus from patient airways and reduced inflammatory proteins thought to cause severe COVID-19 complications.  The study looked at the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19.

READ: BetterLife Pharma signs exclusivity deal to finalize merger with potential coronavirus treatment producer Altum

Dr Eleanor Fish, one of the paper’s authors and a scientific advisor to BetterLife, told Canadian newspaper The Globe and Mail that awareness of interferon as a potential COVID-19 treatment has “been slow to build” and should be prioritized for larger-scale clinical trials.

Interferon describes a family of proteins produced by the body's immune system in response to an invading viral infection, “interfering” with the virus's ability to copy itself.

Cells infected with a typical coronavirus usually fortify its defences and release proteins called chemokines that activate a longer-term response to fighting the virus. In the case of SARS-CoV-2, the specific virus strain that causes COVID-19, the virus blocks the “call to arms” function mediated by interferon.

Research suggests that treatment with interferon is best done early when mild symptoms start to appear.

“The findings lend support to the idea of continuing research efforts, to investigate interferon in larger, blinded trials designed to find more definitive answers,” BetterLife told investors in a statement.

The New York-based company plans to validate the research finding by advancing its intended clinical trials.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: BetterLife Pharma Inc

Price: 0.6914 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $25.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 16/10/20

2 min read